Phase 3 Trial Demonstrates First-in-Class Drug Successfully Reduces Heart Obstruction in Adolescent Patients

ACC.26 trial reveals mavacamten significantly reduces heart obstruction and markers of damage in adolescents with obstructive hypertrophic cardiomyopathy.

By: AXL Media

Published: Mar 30, 2026, 4:03 AM EDT

Source: Information for this report was sourced from American College of Cardiology

A Targeted Breakthrough for Pediatric Hypertrophic Cardiomyopathy

Medical researchers have achieved a significant milestone in treating a life-threatening genetic heart condition in children. According to Joseph William Rossano, chief of cardiology at Children’s Hospital of Philadelphia, the drug mavacamten has proven highly effective in treating adolescents with obstructive hypertrophic cardiomyopathy, or HCM. This disorder causes the heart muscle to thicken abnormally, which often blocks the flow of oxygenated blood into the aorta. While the drug is already approved for adults, this trial represents the first clinical validation of its safety and efficacy in a younger demographic, providing a targeted alternative to older medications that are often less effective or carry greater risks for children.

Addressing the Underlying Pathophysiology of Muscle Contraction

Mavacamten operates as a first-in-class myosin inhibitor, specifically designed to address the mechanical overactivity of the heart muscle. In patients with HCM, the heart's proteins cause it to squeeze with excessive strength, which paradoxically reduces the heart's ability to pump blood effectively and leads to long-term scarring. By inhibiting the protein myosin, the drug reduces this excessive contractile force, allowing the heart chambers to fill more normally. Rossano noted that this approach targets the actual underlying problem of the disease rather than just managing the symptoms, which is a critical advancement for pediatric patients who often face more aggressive forms of the condition than adults.

Quantifying Obstruction Relief in the Scout-HCM Trial

The Phase 3 trial, which followed 44 adolescents across North America, Europe, and Australia, focused on the change in the left ventricular outflow tract gradient. This measurement is a primary indicator of how severely blood flow is being blocked within the heart. Participants receiving mavacamten saw a substantial average drop of 48.5 mmHg in this gradient, while the placebo group saw virtually no change. This reduction in pressure signifies that the physical obstruction caused by the thickened muscle was effectively mitigated, allowing blood to move more freely into the body’s main artery and reducing the strain on the left ventricle.